Blog · Consumer · Published 2026-08-10
GLP-1 Maintenance Doses: Do You Need Tirzepatide or Semaglutide Forever?
For most people, GLP-1 therapy works like treatment for a chronic condition: the benefit persists while the drug does. Trial extensions show substantial regain after full discontinuation — obesity physiology reasserts itself — so "do I need this forever?" has an honest three-part answer: stopping cold usually returns much of the weight; staying at full dose holds results but at full cost and side-effect load; and the growing middle path is a lower maintenance dose — clinician-guided reduction after goal weight, which many patients sustain, though no FDA-labeled "maintenance-dose protocol" exists for either molecule. Maintenance is a dial you tune with a prescriber, not a switch you flip.
Lowering the dose: what the evidence does and doesn't say
The labeled maintenance tiers (tirzepatide 5/10/15 mg; semaglutide 1.7/2.4 mg, now up to 7.2) were validated for reaching and holding loss at those doses. Deliberate step-downs after goal are an extrapolation: dose-response data say lower doses carry real but smaller effect, and clinical practice increasingly uses them — the same evidence gap that powers the microdosing conversation, where sub-label dosing exists precisely because compounded vials allow incremental draws. The physiology behind the whole question — appetite hormones rebounding when signal drops to zero — is laid out in what happens when you stop; maintenance is the strategy of never letting the signal hit zero while minimizing drug, cost, and side effects. Where the dial lands is individual, discovered over months with a prescriber watching weight, appetite, and labs.
The economics of staying on — where structure decides sustainability
Maintenance turns pricing structure into the main variable, because you're now buying years, not a titration sprint. Three structures behave very differently: dose-flat programs cost the same whether you maintain at 5 mg or 15 (NexLife's captured $215/$186 tirzepatide and $165/$145 semaglutide ladders are the reference case — $2,232 and $1,740 upfront on the annual terms); dose-scaled programs reward stepping down, since lower maintenance doses bill less (the surcharge mechanics in reverse); and microdose protocols price the low-signal strategy directly ($110–$189 captured, tracked separately). For covered patients, the ~$50 tier makes brand maintenance the default check. Whatever the lane: get the maintenance-dose price in writing before the titration, because that's the number you'll actually live with — the decision tables carry the dose-behavior column for every ranked program.
Frequently asked questions
Do you have to take tirzepatide or semaglutide forever?
Not necessarily forever — but stopping entirely usually brings substantial regain, so most people who keep results stay on some dose. Maintenance strategies (full dose, reduced dose, or microdose-range signal) are clinician-guided; none is an FDA-labeled protocol.
Can you lower your tirzepatide dose after reaching goal weight?
Many patients do, with a prescriber stepping down and monitoring — dose-response data support smaller-but-real effect at lower doses. It's an individualized process, not a published schedule.
What is a semaglutide maintenance dose?
Labeled maintenance is 1.7 or 2.4 mg weekly (7.2 mg for the HD tier). Off-label maintenance below those doses is common in practice but unvalidated as a protocol — the same evidence status as microdosing.
What does GLP-1 maintenance cost long-term?
Structure decides it: dose-flat programs hold one price at any maintenance dose ($186/$145 effective at the captured floors), dose-scaled programs bill less as you step down, microdose protocols run $110–$189, and covered Medicare patients pay ~$50. Price the maintenance dose, in writing, before you start.
Primary sources
Trial-extension and withdrawal data for both molecules (registration-program extensions); FDA labeling for maintenance tiers; captured program pricing per the methodology. Trial summaries with qualifiers: research journal.
Independent & transparent
Independently operated by US Peptides Partners LLC. Rankings are editorial, computed from published pricing under the methodology, and are not for sale. Outbound provider links carry referral-tracking tags; no arrangement changes a ranking — if a provider out-scores the current leader on captured figures, the ranking changes.